减少大麻使用的远程医疗tDCS:多发性硬化症的试点RCT作为通用使用框架
Giuseppina Pilloni1, Shayna Pehel1, Timothy Ko1
1New York University Grossman School of Medicine, Department of Neurology, 222 East 41st Street, 10th Floor, New York, NY 10017, United States.
Drug and alcohol dependence
|May 16, 2025
概括
这项研究表明,一种远程医疗干预,结合了远程监督的横直流刺激 (RS-tDCS) 和正念冥想,可行且有效地减少多发性硬化症 (MS) 妇女的大麻使用和戒断症状.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 远程医疗服务是远程医疗服务.
背景情况:
- 大麻使用障碍 (CUD) 很普遍,缺乏FDA批准的治疗方法.
- 患有多发性硬化症 (MS) 的女性代表了具有高CUD率的脆弱人群.
- 对CUD需要新的治疗方法,特别是在特定的医疗亚群中.
研究的目的:
- 评估一个月的远程医疗干预对MS妇女CUD的可行性和初步有效性.
- 干预组合了远程监督的跨直流刺激 (RS-tDCS) 与正念冥想.
- 评估对大麻使用,戒断症状和MS相关症状的影响.
主要方法:
- 一项随机对照试验 (RCT) 涉及47名患有MS和CUD的女性.
- 参与者在四周内接受了20次家庭RS-tDCS,目标是左侧脊侧前额叶皮层 (DLPFC).
- 干预与引导的正念冥想配对;可行性通过保留和坚持来评估.
主要成果:
- 高保留率 (83%) 表明远程医疗方法的可行性.
- 活跃的RS-tDCS组显示每周大麻使用和戒断症状显著减少.
- 在活跃组中观察到减少MS相关症状和显著的认知性能改善的趋势.
结论:
- 远程医疗RS-tDCS与正念冥想相结合是一种可行的,有前途的治疗方法,用于MS妇女的CUD.
- 这种方法显示出大规模临床试验和未来临床应用的潜力.
- 强调需要在脆弱的医疗亚群中提供可访问的CUD治疗.
相关概念视频
Drug Therapy
40
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
40
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
204
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
204


